Studies have demonstrated that anti-CD19-CAR T cells could persist for years in patients requiring expensive and recurrent treatments to reconstitute their immunoglobulin levels and protect against opportunistic infections [99, 100]. Here, CD19 is linked to Opportunistic infection.